Nefopam Hydrochloride Brown & Burk Ir

Nefopam Hydrochloride, the active ingredient in Nefopam Hydrochloride Brown & Burk Ir, is a centrally acting analgesic presented as an oral dosage form for oral use. It is used to manage moderate acute pain, post‑operative pain and musculoskeletal pain in adult patients.

GNH USA supplies Nefopam Hydrochloride Brown & Burk Ir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics across diverse therapeutic areas.

Nefopam Hydrochloride is employed to treat pain conditions that involve central nervous system pathways.

- Moderate acute pain: provides analgesia for sudden, short‑term pain episodes such as injury or dental procedures. - Post‑operative pain: helps control pain after surgical interventions, facilitating recovery and mobilization. - Musculoskeletal pain: alleviates pain associated with strains, sprains and other musculoskeletal disorders.

Nefopam Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: feeling of queasiness or urge to vomit. - Dry mouth: reduced salivation leading to oral discomfort. - Sweating: increased perspiration without exertion. - Dizziness: light‑headed sensation, especially when standing quickly. - Tachycardia: elevated heart rate that may be transient.

Serious or Rare Side Effects: - Seizures: risk of convulsive episodes, particularly in predisposed individuals. - Severe hypotension: sudden drop in blood pressure that may cause fainting. - Allergic reactions: rash, itching, swelling, or anaphylaxis in rare cases. - Blood dyscrasias: rare hematologic abnormalities such as leukopenia.

When prescribing Nefopam Hydrochloride, clinicians should consider several precautionary measures to ensure patient safety. - Cardiovascular monitoring: observe heart rate and blood pressure because the drug can cause tachycardia or hypertension. - Seizure risk: avoid use in patients with a history of seizures or epilepsy as it may lower the seizure threshold. - Hepatic impairment: adjust use or monitor closely in patients with liver dysfunction due to hepatic metabolism. - Concomitant MAO inhibitors: do not combine with MAOIs because of potential hypertensive crisis. - Pregnancy and lactation: safety has not been established; use only if benefits outweigh potential risks. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Nefopam Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis due to additive monoamine effects. - Serotonergic agents (SSRIs, SNRIs, tricyclic antidepressants): increased risk of serotonin syndrome. - Antihypertensive drugs: may blunt the drug’s potential to raise blood pressure, leading to unpredictable hemodynamics.

Moderate Interactions (Monitor Closely): - CYP450 inhibitors (e.g., fluoxetine, paroxetine): can raise plasma concentrations of nefopam. - Anticholinergic medications: may exacerbate dry mouth and blurred vision. - Opioid analgesics: concurrent use may mask pain control assessment and increase side‑effect burden.